Anti‐VEGF pathway inhibitors are an attractive therapy for various cancers but have limited therapeutic effects for glioblastoma, such as improvement of radiation necrosis and improvement of ADL because of reduced edema [26, 27, 28]. This evidence concerns the gene VEGFA and glioblastoma.